

Electronic Acknowledgement Receipt

EFS ID:	7735698
Application Number:	09993647
International Application Number:	
Confirmation Number:	1010
Title of Invention:	omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
First Named Inventor/Applicant Name:	Bernd Riedl
Customer Number:	23599
Filer:	Csaba Henter/Caitlin Sickler
Filer Authorized By:	Csaba Henter
Attorney Docket Number:	BAYER 18A
Receipt Date:	03-JUN-2010
Filing Date:	27-NOV-2001
Time Stamp:	10:36:59
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	NPL Documents	P246- SiuPhaseIStudyofOralRaf1Kinas einhibitor.pdf	63765 1c1e419fb190b49ffb58da67140cea5d5008 c995	no	1

Warnings:

Information:

2	NPL Documents	P247-SIUETAL-SorafenibGemcitabine.pdf	718389	no	8
			31b86a519e5abd5c1f9970bfd487b25a2ddb53c8		
Warnings:					
Information:					
3	NPL Documents	P248-SmithDiscoveryofHeterocyclicUreasasaNewClassofRafKinaseInhibitors.pdf	355827	no	4
			07d6281e045dd31dee0a0ead92df3665cfa3ff65		
Warnings:					
Information:					
4	NPL Documents	P249-SMITHETAL-RecentAdvancesRAF.pdf	38048	no	1
			80e0b2f242fc280afe3ba0c3b2cd1416c59bfa02		
Warnings:					
Information:					
5	NPL Documents	P250-SMYTHANCHIMERICASSISTANCE.pdf	392680	no	4
			1fe8092d62a9145caf65ffc747903280a756554		
Warnings:					
Information:					
6	NPL Documents	P251-SongetalCrossHostEvolution.pdf	857525	no	6
			8ec532df02b5b73c1d8159922547d1e0a3a836e9		
Warnings:					
Information:					
7	NPL Documents	P252-Sorbaraetal-Bay43-9006DrugsoftheFuture.pdf	871913	no	7
			f3e16a925c31fc427b97bf921b166fb0ce29a85b		
Warnings:					
Information:					
8	NPL Documents	P253-vanSpronsenNovelTreatmentStrategiesinClear-CellMetastaticRenalCellCarcinoma.pdf	917166	no	9
			a19d6c6d5fce79324a9cddde02aab7c68805e1e3		
Warnings:					
Information:					
9	NPL Documents	P253a-Stadler-et-al-Clinical-Cancer-Res-v10-p3365.pdf	99830	no	6
			abc1fb757e5c041ae975126a93b1ffc9e660c9ae		
Warnings:					
Information:					
10	NPL Documents	P254-STAJLJILLMETALDEREGULATEDAKT3ACTIVITYPROMOTESDEVELOPMENTOFMALIGNANTMELANOMA.pdf	1160360	no	8
			fi6bb64520f6c2201e63ce6c19134bd8c179687c		
Warnings:					
Information:					

11	NPL Documents	P255-STAVCHANSKY-EvaulationofBioavailabilityofaSolidDispersion.pdf	448101 9c5a60f220742f39586ebf1bbe9a6a3aed15fb48	no	4
Warnings:					
Information:					
12	NPL Documents	P256-SteinInternalMedicineFourthEdition.pdf	1591775 5c511b9f56b692ce322744eddf79180c655b9bbb	no	19
Warnings:					
Information:					
13	NPL Documents	P257-STERNBERG-ConspiracyTheory.pdf	166139 a99338de21bc21a2cb56dc8171fd0a4898c67c3a	no	4
Warnings:					
Information:					
14	NPL Documents	P258-StellaProdrugsandSite-SpecificDrugDelivery.PDF	1045221 dca5f2034d38c6722e78bc1bb3b0291930fa6236	no	9
Warnings:					
Information:					
15	NPL Documents	P259-StellaetalProdrugsasTherapeutics.pdf	409329 71597d36fdb2eb544c97bdd0ad1770aa9ab83f93	no	4
Warnings:					
Information:					
16	NPL Documents	P260-StellaProdrugsDotheyHaveAdvantagesinClinicalPractice.PDF	1542203 e179ded802b141e160f0ee43ef507f0ce500874f	no	19
Warnings:					
Information:					
17	NPL Documents	P260a-StevensonPhaseI Clinical.pdf	823200 7f0391227b86f5ac34d89dad7a3b888ac095b22d	no	10
Warnings:					
Information:					
18	NPL Documents	P261-StocketalIntegrityofcRAF-1MEK.pdf	647970 e855dcc0745bcaa576e4f71bb7634d48b63d4917	no	7
Warnings:					
Information:					
19	NPL Documents	P262-STOKOETAL-ActivationC-RAF1.pdf	1415429 3d0612a43195f04e99b3469c606e1c95cb236bad	no	13
Warnings:					
Information:					

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.